

MAILED
APR 22 2005
DATE CANCELLED

MODIFIED PTO/SB/08 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application Number	10/002,634
Date Submitted: April 20, 2005		Filing Date	12/5/2001
(use as many sheets as necessary)		First Named Inventor	Anthony E. BOLTON
		Group Art Unit	1644
		Examiner Name	Belyavskiy, M. A.
		Attorney Docket Number	355908-2500

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Office ³	Number ⁴	Kind Code ⁵ (if known)			

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
MB	C1	Abbot, et al., Royal Society of Edinburgh Workshop on ME/CIS, "New developments in the biology of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome" Dundee, UK (October 3, 2003)	
	C2	Natelson et al. "Evidence for the Presence of Immune Dysfunction in Chronic Fatigue Syndrome" <i>Clinical and Diagnostic Immunology</i> 9:747-752 (2002)	
	C3	Patarca-Montero et al. "Immunology of Chronic Fatigue Syndrome" <i>J. of Chronic Fatigue Syndrome</i> 6:69-107	
MB	C4	Klein et al. "High Incidence of Antibodies to 5-Hydroxytryptamine, Gangliosides and Phospholipids in Patients with Chronic Fatigue and Fibromyalgia Syndrome and their Relatives: Evidence for a Clinical Entity of Both Disorders" <i>Eur J Med Res</i> 1:21-26 (1995/96)	

Examiner Signature		Date Considered	6/29/05
--------------------	---	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.